Chordate Medical Holding AB (OSTO:CMH) Revenue: kr0.99 Mil (TTM As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:CMH Chordate Medical Holding AB OSTO:CMH
46 GF Score
Price kr0.16
View Full Analysis

What is Chordate Medical Holding AB Revenue?

Chordate Medical Holding AB OSTO:CMH -60.40% 46 Revenue is kr0.99 Mil as of Jun. 2025. GuruFocus rates OSTO:CMH with a GF Score™ of 46/100.

Chordate Medical Holding AB's revenue for the three months ended in Jun. 2025 was kr0.16 Mil. Its revenue for the trailing twelve months (TTM) ended in Jun. 2025 was kr0.99 Mil. Chordate Medical Holding AB's Revenue per Share for the three months ended in Jun. 2025 was kr0.06. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2025 was kr0.58.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.


Chordate Medical Holding AB  (OSTO:CMH) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Chordate Medical Holding AB Revenue Related Terms


Chordate Medical Holding AB Revenue Historical Data

* Premium members only.

The historical data trend for Chordate Medical Holding AB's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chordate Medical Holding AB Revenue Chart

Chordate Medical Holding AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.62 0.88 0.11 0.98 0.67

Chordate Medical Holding AB Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.17 0.15 0.09 0.60 0.16

OSTO:CMH vs ABT, SYK, MDT: Revenue Comparison

For the Medical Devices subindustry, Chordate Medical Holding AB's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chordate Medical Holding AB Revenue vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Chordate Medical Holding AB's Revenue distribution charts can be found below:

* The bar in red indicates where Chordate Medical Holding AB's Revenue falls into.


OSTO:CMH
46GF Score
Chordate Medical Holding AB OSTO:CMH
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chordate Medical Holding AB Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.99 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of kr0.99 Mil mean?
Chordate Medical Holding AB (OSTO:CMH) has a Revenue of kr0.99 Mil as of Jun. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on Chordate Medical Holding AB and its competitors.
Is Chordate Medical Holding AB's Revenue too high?
Chordate Medical Holding AB's current Revenue is kr0.99 Mil. Overall, Chordate Medical Holding AB has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Chordate Medical Holding AB's Revenue compare to ABT and SYK?
Chordate Medical Holding AB's Revenue of kr0.99 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Medical Devices & Instruments company?
A good Revenue depends on the Medical Devices & Instruments industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Chordate Medical Holding AB and its competitors. Chordate Medical Holding AB's current Revenue is kr0.99 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chordate Medical Holding AB stock overvalued right now?
Chordate Medical Holding AB (OSTO:CMH) has a current Revenue of kr0.99 Mil. The current Revenue is kr0.99 Mil. Chordate Medical Holding AB's overall GF Score™ is 46/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Chordate Medical Holding AB (OSTO:CMH), the current Revenue is kr0.99 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Chordate Medical Holding AB Business Description

Address Farogatan 33, 164 51 Kista, Kista, SWE, 164 40
Chordate Medical Holding AB is a medical technology company that has developed patented and CE-marked a new nerve-modulating treatment technology for chronic nasal congestion and chronic migraine. The company sells its products in Selected European markets, Israel, and Saudi Arabia. The company's product range is based on the CE-marked treatment units Chordate System S100 and S120 for rhinitis and S220 for migraine, registered for the indications of preventive treatment of chronic migraine and chronic rhinitis and use on patients. The company sells its product system, including treatments, through distributors to clinics and hospitals in its primary markets.
46GF Score

Get the complete analysis for OSTO:CMH

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.16
Price